Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 7/20 | 0.34 |
| ▸ | COMT | P21964 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2266766 | 0.90 | HSD17B13 (0.35) | HSD17B13IGF1RPPARGPPARACREBBP | |
| SCHEMBL2265508 | 0.89 | MET (0.34) | HSD17B13IGF1RPPARGPPARAALDH1A1 | |
| SCHEMBL2261414 | 0.89 | HSD17B13 (0.42) | HSD17B13MET | |
| SCHEMBL12517938 | 0.89 | ALKBH1 (0.39) | PPARGPPARA | |
| SCHEMBL2265443 | 0.89 | PPARG (0.36) | HSD17B13IGF1RPPARGPPARAMET | |
| SCHEMBL2221751 | 0.88 | IGF1R (0.40) | IGF1RMET | |
| SCHEMBL13274906 | 0.88 | IGF1R (0.34) | IGF1RPPARGPPARAALDH1A1KDM4E | |
| SCHEMBL13275026 | 0.87 | SYK (0.33) | HSD17B13IGF1RPPARGPPARAALDH1A1 | |
| SCHEMBL2228967 | 0.86 | MCHR1 (0.32) | HSD17B13IGF1RPPARGPPARAMET | |
| SCHEMBL13275278 | 0.86 | MET (0.39) | IGF1RPPARGPPARAMETTAS2R8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | HSD17B13 3914/4885IGF1R 152/4885COMT 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.